Beta Drugs Limited has informed the Exchange about Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Completion of Acquisition of Shares of Nivian Lifesciences Private Limited
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs Limited has completed the acquisition of 10,94,535 equity shares (66.09%) of Nivian Life Sciences Private Limited. Shares representing 64.26% of equity capital were transferred by April 30, 2026, and the remaining shares were transferred on May 22, 2026. As a result, Nivian Life Sciences became a subsidiary of Beta Drugs in April 2026. The company will now initiate the process for NSE listing approval for the share swap arrangement, followed by electronic credit of shares through corporate action. This was disclosed in compliance with Regulation 30 of SEBI LODR Regulations, 2015.
The acquisition gives Beta Drugs majority control over Nivian Life Sciences as a subsidiary, expanding its portfolio. The share swap and listing process suggests a potential corporate restructuring or consolidation for the target entity.